New Findings in Cancer Therapy Described from Kangwon National University [Poly(styrene)-b-poly(DL-lactide) copolymer-based nanoparticles for anticancer drug delivery]
By a News Reporter-Staff News Editor at Biotech Week -- A new study on Oncology is now available. According to news reporting originating from Chunchon, South Korea, by NewsRx correspondents, research stated, "Poly(styrene)-b-poly(DL-lactide) (PS-PDLLA) copolymer-based nanoparticles (NPs) of a narrow size distribution, negative zeta potential, and spherical shape were fabricated for the delivery of docetaxel (DCT). The particle size was consistently maintained in serum for 24 hours and a sustained drug release pattern was observed for 10 days in the tested formulations."
Our news editors obtained a quote from the research from Kangwon National University, "The cytotoxicity of the developed blank NPs was negligible in prostate cancer (PC-3) cells. Cellular uptake and distribution of the constructed NPs containing a hydrophobic fluorescent dye was monitored by confocal laser scanning microscopy (CLSM) for 24 hours. Anti-tumor efficacy of the PS-PDLLA/DCT NPs in PC-3 cells was significantly more potent than that of the group treated with commercially available DCT, Taxotere(®) (P < 0.05). Blood biochemistry tests showed that no serious toxicity was observed with the blank NPs in the liver and kidney. In a pharmacokinetic study of DCT in rats, in vivo clearance of PS-PDLLA/DCT NPs decreased while the half-life in blood increased compared to the Taxotere-treated group (P < 0.05)."
According to the news editors, the research concluded: "The PS-PDLLA NPs are expected to be a biocompatible and efficient nano-delivery system for anticancer drugs."
For more information on this research see: Poly(styrene)-b-poly(DL-lactide) copolymer-based nanoparticles for anticancer drug delivery. International Journal of Nanomedicine, 2014;9():2803-2813. International Journal of Nanomedicine can be contacted at: Dove Medical Press Ltd, PO Box 300-008, Albany, Auckland 0752, New Zealand (see also Oncology).
The news editors report that additional information may be obtained by contacting J.Y. Lee, Kangwon Natl Univ, Coll Pharm, Chunchon 200701, South Korea. Additional authors for this research include J.S. Kim, H.J. Cho and D.D. Kim.
Keywords for this news article include: Asia, Therapy, Chunchon, Oncology, South Korea, Nanoparticle, Nanotechnology, Drug Delivery Systems, Emerging Technologies
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC